Veterinary Cardiologist, CEO Evolution Veterinary Specialists Evolution Veterinary Specialists Golde, Colorado, United States
Presentation Description / Summary: The purpose of this prospective study evaluate how echocardiographic parameters and NT-proBNP concentrations change over time in canines with Stage B2 MMVD receiving pimobendan therapy, and determine whether changes in these measures correlate.
Learning Objectives:
Describe the pathophysiology and clinical staging of myxomatous mitral valve disease (MMVD), with emphasis on ACVIM Stage B2 criteria.
Explain the pharmacologic effects and clinical benefits of pimobendan in delaying the onset of congestive heart failure in dogs with Stage B2 MMVD.
Identify key echocardiographic parameters used to monitor MMVD progression, including LA:Ao ratio, LVIDDn, and fractional shortening.
Interpret changes in NT-proBNP levels as indicators of cardiac wall stress and correlate these findings with echocardiographic trends.
